NCT07502768 2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2 Not yet recruiting
Clinical Trials
13 trialsNCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05977673 2025-12-08
FIL_Tisle-HL
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT07031700 2025-06-22
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06761911 2025-01-07
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Dalian Medical University
Phase 4 Not yet recruiting
NCT05477264 2024-04-03
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Samsung Medical Center
Phase 2 Recruiting
NCT05627115 2023-11-29
RATiFY
University College, London
Phase 2 Not yet recruiting
NCT05833984 2023-04-27
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05659628 2022-12-21
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Ningbo No. 1 Hospital
Phase 1 Recruiting
NCT04539444 2021-08-02
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT04843267 2021-04-13
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Sun Yat-sen University
Phase 2 Unknown